Jennison Associates Portfolio holdings
Jennison Associates, founded in 1969 and headquartered in New York City, is a global investment management firm managing over $194 billion in assets as of late 2024, specializing in active equity and fixed-income strategies. A subsidiary of PGIM, the asset management arm of Prudential Financial, Jennison serves a diverse client base—including institutions, sub-advisory clients, public plans, endowments, and corporations—with a focus on fundamental research, bottom-up portfolio construction, and high-conviction investing. Known for its equity expertise across styles, geographies, and market capitalizations, as well as investment-grade fixed-income offerings, the firm employs seasoned portfolio managers averaging 29 years of industry experience and 16 years with Jennison. With additional offices in Boston and a culture emphasizing intellectual rigor and long-term client outcomes, Jennison has built a reputation for excellence and stability in the investment management industry.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Advanced Micro Devices
AMD
|
+$1.32B |
| 2 |
AstraZeneca
AZN
|
+$733M |
| 3 |
Microsoft
MSFT
|
+$728M |
| 4 |
Cadence Design Systems
CDNS
|
+$720M |
| 5 |
Moody's
MCO
|
+$359M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Alcon
ALC
|
+$1.43B |
| 2 |
Estee Lauder
EL
|
+$872M |
| 3 |
Eli Lilly
LLY
|
+$626M |
| 4 |
Netflix
NFLX
|
+$521M |
| 5 |
UnitedHealth
UNH
|
+$466M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 33.19% |
| 2 | Consumer Discretionary | 19.62% |
| 3 | Healthcare | 16.16% |
| 4 | Financials | 9.12% |
| 5 | Communication Services | 8.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
XYZ
576
Block Inc
XYZ
$50.1B
| $259K | ﹤0.01% |
+3,775
| New | +$283K |
|
577
Timken Company
TKR
$9.13B
| $252K | ﹤0.01% |
3,087
| – | – |
|
578
Medpace
MEDP
$16.4B
| $250K | ﹤0.01% |
1,330
-279
| -17% | -$57.7K |
|
579
ProFrac Holding
ACDC
$814M
| $241K | ﹤0.01% |
19,043
-259,238
| -93% | -$5.04M |
|
580
BP
BP
$106B
| $215K | ﹤0.01% |
+5,669
| New | +$212K |
|
581
State Street SPDR S&P MIDCAP 400 ETF Trust
MDY
$27B
| $204K | ﹤0.01% |
445
-682
| -61% | -$318K |
|
582
Arbor Realty Trust
ABR
$963M
| – | – |
-55,592
| Closed | -$733K |
|
583
Axcelis
ACLS
$4.18B
| – | – |
-10,997
| Closed | -$873K |
|
584
Adient
ADNT
$1.61B
| – | – |
-18,492
| Closed | -$641K |
|
|
AIV
585
Aimco
AIV
$384M
| – | – |
-90,199
| Closed | -$642K |
|
|
586
Alcon
ALC
$34.4B
| – | – |
-4,532,442
| Closed | -$1.43B |
|
587
Altimmune
ALT
$591M
| – | – |
-928,813
| Closed | -$15.3M |
|
588
AnaptysBio
ANAB
$1.63B
| – | – |
-19,802
| Closed | -$614K |
|
589
Apple Hospitality REIT
APLE
$3.91B
| – | – |
-66,968
| Closed | -$1.06M |
|
590
Booz Allen Hamilton
BAH
$8.65B
| – | – |
-23,848
| Closed | -$2.49M |
|
591
Bally's
BALY
$688M
| – | – |
-71,483
| Closed | -$1.39M |
|
592
BancFirst
BANF
$3.83B
| – | – |
-6,668
| Closed | -$588K |
|
|
BBT
593
Beacon Financial Corp
BBT
$2.68B
| – | – |
-30,384
| Closed | -$908K |
|
|
BLUE
594
DELISTED
bluebird bio
BLUE
| – | – |
-5,328
| Closed | -$737K |
|
595
Citigroup
C
$231B
| – | – |
-45,119
| Closed | -$2.04M |
|
|
CADE
596
DELISTED
Cadence Bank
CADE
| – | – |
-26,875
| Closed | -$663K |
|
597
Crown Holdings
CCK
$13.3B
| – | – |
-996,923
| Closed | -$82M |
|
598
California Resources
CRC
$4.56B
| – | – |
-183,440
| Closed | -$7.98M |
|
599
CVB Financial
CVBF
$4.03B
| – | – |
-60,285
| Closed | -$1.55M |
|
600
Clearway Energy Class C
CWEN
$4.85B
| – | – |
-1,061,389
| Closed | -$33.8M |
|
Similar funds
Jennison Associates's Q1 2023 Portfolio in Review
As of Q1 2023, Jennison Associates held 644 positions worth $109B, up 10% from $98.7B the previous quarter. Its ten largest holdings account for 39% of the portfolio.
Jennison Associates withdrew a net $3.94B in Q1 2023, closing 63 positions and reducing 280 holdings. Its most notable exit was Alcon, an estimated $1.43B position sold in full.
By sector, the portfolio is most concentrated in Technology at 33% of assets, up from 26% a quarter earlier, followed by Consumer Discretionary and Healthcare.
Against the trend, Jennison Associates opened a new position in Advanced Micro Devices worth $1.59B.
- Jennison Associates's largest Q1 2023 buy was Advanced Micro Devices: 16,272,765 shares worth $1.59B.
- Jennison Associates added most to AstraZeneca in Q1 2023, an estimated $733M increase.
- Jennison Associates's biggest Q1 2023 reduction was Estee Lauder, cutting an estimated $872M.
- Jennison Associates fully exited Alcon in Q1 2023, selling an estimated $1.43B.
- Jennison Associates's ten largest holdings make up 39% of its $109B portfolio in Q1 2023.
- Jennison Associates opened 73 new positions and closed 63 in Q1 2023.
- Jennison Associates's portfolio value rose 10% quarter-over-quarter to $109B.
Based on Jennison Associates's 13F filing for Q1 2023, filed 26 Apr 2023.